Pfizer Scraps Weight Loss Pill After Trial Setback Amidst Counterfeit Drug Alert

Pfizer's Weight Loss Pill Development Halted

• 💊 Pfizer has reversed course on developing a daily weight loss pill after a patient in its trial experienced drug-induced liver injury.
• 📉 The company's once-daily GLP1 pill, intended to compete in the booming weight loss market, has been officially scrapped.
• 🎯 Despite this setback, Pfizer remains committed to developing innovative medicines and has another weight loss pill targeting the GIPR hormone in phase 2 trials.

The Booming Weight Loss Market

• 📈 The weight loss market is projected to be worth approximately $150 billion in the coming years, driven by the popularity of weight loss injections.
• 🏆 Competitors like Lily and Novo have been leading this market, with their makers also working on weight loss pills in late-stage clinical trials.

Counterfeit Drug Alert for Weight Loss Injections

• ⚠️ The FDA has issued a warning about counterfeit Ozempic now circulating on the market from resellers and unauthorized distributors.
• 🚨 The identified counterfeit injections have a lot number P0362 and a serial number beginning with 517.
• 🛒 Patients are strongly advised to purchase medications only from licensed pharmacies.
• 🔬 The FDA and Ozempic's maker are currently testing the counterfeit products to assess their safety.